Providing Access to the Latest Cancer Clinical Trials
Thanks to our affiliation with Duke Medicine, people with cancer have access to cutting-edge therapies available in clinical trials. Our clinical trials program is approved by the Cancer and Leukemia Group B, a national clinical research group sponsored by the National Cancer Institute. Our cancer center staff works closely with the Duke Oncology Network to choose appropriate trials. To date, many of our trials have focused on lung, breast, colon and prostate cancer.
Current breast cancer trials:
- Patients with newly diagnosed stage 0-IIIA breast cancer can enroll in a radiation study. (Protocol WFU 97609)
- Patients with HER2-positive breast cancer can enroll in a study testing drugs that protect heart function during Herceptin treatment. (Protocol SCUSF 0806)
- Patients with early stage HER2-low breast cancer can enroll in a study to see if adding Herceptin to standard treatment reduces recurrence risk. (Protocol NSABP B 47)
- Patients with node-positive or high-risk, node-negative HER2-negative breast cancer can enroll in a study of chemotherapy drugs. (Protocol NSABP B 49)
Current lung cancer trials:
- Patients with Stage IIIB or IV non-small cell lung cancer who have not had chemotherapy can enroll in a study to see whether receiving sunitinib after chemotherapy will affect their tumor. (Protocol 30607)
To learn more, call 843-522-7819.